Treatment of Opioid Use Disorder Half & Half Waiver Training

October 15, 2020

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training necessary for prescribers to obtain a waiver to engage in office‐based treatment of opioid use disorders with buprenorphine. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and the Providers Clinical Support System (PCSS.) The Treatment of Opioid Use Disorder Course covers all evidence-based practices and medications for treating patients with opioid use disorder.

Practice Gaps and Needs

In order to apply for a DEA DATA 2000 waiver, physicians, nurse practitioners, and physician assistants must complete four hours live and four hours of online education to prescribe buprenorphine for the treatment of opioid use disorders in an office-based setting. Providers lack the knowledge base required to screen and identify patients experiencing Opioid Use Disorder and define evidence-based treatments. Additionally, providers need additional training in order to utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.

Elements of Competence

This continuing education (CE) activity is designed to change learner competence and focuses on the American Board of Medical Specialties areas of medical knowledge, professionalism, and patient care and procedural skills. This activity also focuses on the interprofessional competencies of values/ethics for interprofessional practice and roles and responsibilities.

Target Audience

This activity is designed to meet the needs of physicians, nurse practitioners, and physician assistants in Family & Community Medicine. 

Learning Objectives

By participating in this activity learners will be able to: 

  • illustrate the importance of obtaining a waiver to begin treating patients with OUD.
  • describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
  • screen and identify patients with OUD and define evidence-based treatments.
Course summary
Available credit: 
  • 4.25 AAPA Category 1 CME
  • 4.25 AMA PRA Category 1 Credit
  • 4.25 ANCC Contact Hours
  • 4.25 University of Wisconsin–Madison Continuing Education Hours
Registration opens: 
10/07/2020
Course expires: 
12/31/2020
Event starts: 
10/15/2020 - 12:30pm
Event ends: 
10/15/2020 - 5:00pm
Cost:
$0.00
Rating: 
0
Treatment of Opioid Use Disorder Half and Half MAT Waiver Training Agenda

October 15th, 2020

12:30 pmWelcome & IntroductionRandy
12:40 pmOverview of MAT WaiverRandy
1:10 pmPharmacologyTovar
1:40 pmPatient EvaluationKelly
2:20 pmCase Studies Group
Break
2:30 pm Special Topics in WaiversRandy
3:15 pmMAT Clinical AppKelly
3:45 pmUrine Drug TestingTovar
Break
4:25 pmCases Review - NotificationRandy
4:55 pmReview Resources & Wrap UpGroup

 

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership, that the faculty, authors, planners, and other persons who may influence content of this CE activity disclose all relevant financial relationships with commercial interests in order to allow CE staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation(s). Detailed disclosures will be made in the workshop materials.

Disclosures will be provided prior to the start of the workshop.

*The ACCME, ACPE, and ANCC defines a commercial interest as any entity producing, marketing, re‐selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME, ACPE, and ANCC does not consider providers of clinical service directly to patients to be commercial interests.

The University of Wisconsin provides equal opportunities in employment and programming, including Title IX requirements. The University of Wisconsin fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact help@icep.wisc.edu

Please review full disclosures here

Discloser List CME Internal Report

 

Joint Accreditation Provider Logo

Accreditation Statement

In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live online activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Designation Statement

The University of Wisconsin–Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.25 AAPA Category 1 CME credits. Approval is valid until 6/30/2022. PAs should only claim credit commensurate with the extent of their participation.

American Nurses Credentialing Center (ANCC) 

The University of Wisconsin–Madison ICEP designates this live onlinee activity for a maximum of 4.25 ANCC contact hours. The University of Wisconsin-Madison School of Nursing is Iowa Board of Nursing provider 350.

Continuing Education Units (CEUs)

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.425 CEUs or 4.25 hours.

 

 

Available Credit

  • 4.25 AAPA Category 1 CME
  • 4.25 AMA PRA Category 1 Credit
  • 4.25 ANCC Contact Hours
  • 4.25 University of Wisconsin–Madison Continuing Education Hours

Price

Cost:
$0.00
Please login or register to take this course.